LV12251B - 2-fenil-1,2-benzizoselenazol-3(2h)-ona pielietojums medikamenta ražošanai, kas paredzēts alcheimera slimības profilaksei un/vai terapijai - Google Patents

2-fenil-1,2-benzizoselenazol-3(2h)-ona pielietojums medikamenta ražošanai, kas paredzēts alcheimera slimības profilaksei un/vai terapijai Download PDF

Info

Publication number
LV12251B
LV12251B LVP-98-231A LV980231A LV12251B LV 12251 B LV12251 B LV 12251B LV 980231 A LV980231 A LV 980231A LV 12251 B LV12251 B LV 12251B
Authority
LV
Latvia
Prior art keywords
die
der
alzheimer
verbindung
das
Prior art date
Application number
LVP-98-231A
Other languages
English (en)
Latvian (lv)
Other versions
LV12251A (lv
Inventor
Ikuo Maruyama
Kazuhiro Abeyama
Hiroyuki Masayasu
Original Assignee
A.Nattermann & Cie Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A.Nattermann & Cie Gmbh filed Critical A.Nattermann & Cie Gmbh
Publication of LV12251A publication Critical patent/LV12251A/xx
Publication of LV12251B publication Critical patent/LV12251B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
LVP-98-231A 1996-08-27 1998-10-22 2-fenil-1,2-benzizoselenazol-3(2h)-ona pielietojums medikamenta ražošanai, kas paredzēts alcheimera slimības profilaksei un/vai terapijai LV12251B (lv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22551296 1996-08-27
PCT/DE1997/000701 WO1998008511A1 (de) 1996-08-27 1997-04-07 Verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-one zur herstellung einer pharmazeutischen zubereitung für die behandlung der alzheimer-krankheit

Publications (2)

Publication Number Publication Date
LV12251A LV12251A (lv) 1999-04-20
LV12251B true LV12251B (lv) 1999-08-20

Family

ID=16830487

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-98-231A LV12251B (lv) 1996-08-27 1998-10-22 2-fenil-1,2-benzizoselenazol-3(2h)-ona pielietojums medikamenta ražošanai, kas paredzēts alcheimera slimības profilaksei un/vai terapijai

Country Status (29)

Country Link
US (1) US5948800A (no)
EP (1) EP0826370B1 (no)
KR (1) KR20000035859A (no)
CN (1) CN1112922C (no)
AT (1) ATE219361T1 (no)
AU (2) AU3866997A (no)
BR (1) BR9711259A (no)
CA (1) CA2213794C (no)
CZ (1) CZ295364B6 (no)
DE (2) DE59707550D1 (no)
DK (1) DK0826370T3 (no)
EE (1) EE03953B1 (no)
ES (1) ES2177849T3 (no)
FI (1) FI119622B (no)
HK (1) HK1020317A1 (no)
HU (1) HU225264B1 (no)
IL (1) IL127113A (no)
LT (1) LT4602B (no)
LV (1) LV12251B (no)
NO (1) NO312812B1 (no)
NZ (1) NZ332292A (no)
PL (1) PL188481B1 (no)
PT (1) PT826370E (no)
SI (1) SI9720060B (no)
TR (1) TR199700858A2 (no)
TW (1) TW501925B (no)
UA (1) UA59367C2 (no)
WO (2) WO1998008511A1 (no)
ZA (1) ZA977644B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE190487T1 (de) * 1993-10-27 2000-04-15 Daiichi Seiyaku Co Granuläre zubereitung
JP2000016935A (ja) * 1998-07-01 2000-01-18 Dai Ichi Seiyaku Co Ltd シクロオキシゲナーゼ阻害剤
EP1174423A4 (en) * 1999-03-31 2008-03-19 Arne Holmgren SUBSTRATES FOR THIOREDOXINE REDUCTASE
WO2003010153A1 (en) 2001-07-26 2003-02-06 Samsung Electronics Co. Ltd. N-alkyl-n-phenylhydroxylamine compounds containing metal chelating groups, their preparation and their therapeutic uses
WO2003010154A1 (en) 2001-07-26 2003-02-06 Samsung Electronics Co. Ltd. Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses
WO2003010143A1 (en) 2001-07-26 2003-02-06 Samsung Electronics Co., Ltd. Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses
GB201102248D0 (en) 2011-02-09 2011-03-23 Isis Innovation Treatment of bipolar disorder
CN103965188A (zh) * 2013-01-29 2014-08-06 中山大学 含硒多奈哌齐类似物
EP2950102A1 (en) 2014-05-30 2015-12-02 Biocross, S.L. Method for the diagnosis of alzheimer s disease and mild cognitive impairment
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
EP3067699A1 (en) 2015-03-11 2016-09-14 Neuron Bio, S.A. Method for diagnosing alzheimer's disease
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
CN113116888B (zh) * 2021-04-19 2022-08-26 上海兴糖生物技术有限公司 依布硒啉的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3616923A1 (de) * 1986-05-20 1987-11-26 Nattermann A & Cie Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on
DE3638124C2 (de) * 1986-11-08 1996-09-05 Nattermann A & Cie Neue pharmazeutische Verwendung von Ebselen
JPH01131113A (ja) * 1987-08-27 1989-05-24 Dai Ichi Seiyaku Co Ltd 脳障害治療剤
JPH0238591A (ja) 1988-07-27 1990-02-07 Fujikura Ltd 高純度銅の製造方法
DE4024885C2 (de) * 1990-08-06 2002-07-18 Nattermann A & Cie Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
US5385726A (en) * 1990-08-06 1995-01-31 Rhone-Poulenc Rorer Gmbh Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one
FR2669633B1 (fr) * 1990-11-23 1993-01-22 Adir Nouveaux derives de la benzoselenazolinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH07233056A (ja) * 1993-09-03 1995-09-05 Dai Ichi Seiyaku Co Ltd リポキシゲナーゼ阻害剤

Also Published As

Publication number Publication date
PT826370E (pt) 2002-10-31
PL321796A1 (en) 1998-03-02
IL127113A0 (en) 1999-09-22
EE9900007A (et) 1999-06-15
ATE219361T1 (de) 2002-07-15
TW501925B (en) 2002-09-11
WO1998008831A1 (fr) 1998-03-05
DE59707550D1 (de) 2002-07-25
SI9720060A (sl) 1999-06-30
US5948800A (en) 1999-09-07
FI982689A (fi) 1998-12-11
AU3529897A (en) 1998-03-05
EP0826370B1 (de) 2002-06-19
IL127113A (en) 2003-07-06
AU3866997A (en) 1998-03-19
DE19733690A1 (de) 1998-03-26
DK0826370T3 (da) 2002-10-07
LV12251A (lv) 1999-04-20
BR9711259A (pt) 1999-08-17
UA59367C2 (uk) 2003-09-15
AU725534B2 (en) 2000-10-12
HU225264B1 (en) 2006-08-28
WO1998008511A1 (de) 1998-03-05
CN1223580A (zh) 1999-07-21
CA2213794C (en) 2006-10-03
ES2177849T3 (es) 2002-12-16
EP0826370A1 (de) 1998-03-04
CZ31799A3 (cs) 1999-11-17
FI982689A0 (fi) 1998-12-11
HK1020317A1 (en) 2000-04-14
PL188481B1 (pl) 2005-02-28
NO973912D0 (no) 1997-08-26
KR20000035859A (ko) 2000-06-26
NO973912L (no) 1998-03-02
TR199700858A2 (xx) 1998-03-21
FI119622B (fi) 2009-01-30
CN1112922C (zh) 2003-07-02
CZ295364B6 (cs) 2005-07-13
CA2213794A1 (en) 1998-02-27
NO312812B1 (no) 2002-07-08
HUP9903213A3 (en) 2000-12-28
LT4602B (lt) 2000-01-25
ZA977644B (en) 1999-02-26
EE03953B1 (et) 2003-02-17
SI9720060B (en) 2001-12-31
NZ332292A (en) 2001-07-27
HUP9903213A1 (en) 2000-07-28
LT99016A (en) 1999-10-25

Similar Documents

Publication Publication Date Title
DE69532031T2 (de) Schilddrüsenhormone enthaltende mittel
LV12251B (lv) 2-fenil-1,2-benzizoselenazol-3(2h)-ona pielietojums medikamenta ražošanai, kas paredzēts alcheimera slimības profilaksei un/vai terapijai
EP2072054B1 (de) Verwendung eines Extraktes aus Blättern von Ginkgo biloba
DE4321444A1 (de) Pharmazeutische Zubereitung
DE69433012T2 (de) Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac
DE2520978C3 (de) Dosierungseinheit einer festen, oral zu verabreichenden Arzneiform von wasserlöslichen Xanthin-Derivaten
EP0591363A1 (de) Torasemid-haltige pharmazeutische zusammensetzungen
DE3638124C2 (de) Neue pharmazeutische Verwendung von Ebselen
DE19910682B4 (de) Verwendung eines Kombinationspräparates zur Therapie einer Fibrat-induzierten Hyperhomocysteinämie
DE60308899T2 (de) Quaternäre verbindungen enthaltend propolis als wirkstoff
EP0164571B1 (de) Retardformen des alpha-(2,5-Dimethoxy-phenyl)-beta-lycinamido-äthanols und Verfahren zu ihrer Herstellung
DE2707095A1 (de) Isopropylaminopyrimidinorthophosphat
DE60212757T2 (de) Verfahren zur Verwendung von Pyrrolederivaten gegen Zwangsstörungen
WO2000001392B1 (de) 1-octadecyl-2-methyl-sn-glycero-3-phosphocholin (et180ch3) zur behandlung von humanen mammakarzinomen
WO1996034607A1 (de) Kombinationspräparate mit vaskulärer wirkung, welche dihydropyridine, acetylsalicylsäure-nitroester und vitamine enthalten
DE60202446T2 (de) Pharmazeutische formulierung und ihre verwendung für die herstellung eines medikaments zur behandlung von herz-kreislauf-erkrankungen
DE2937489A1 (de) Arzneimittel zur behandlung hypertoner funktionszustaende der harnblase
DE2128730A1 (de) Mittel zur Kompensierung eines Dopaminmangels im Gehirn
DE3439055A1 (de) Substituierte 4h-3,1 benzoxazine und ein benzodiazepin-derivat enthaltendes arzneimittel
EP0098475A2 (de) Pharmazeutische Zusammensetzung, ihre Herstellung und Verwendung
DE4023136A1 (de) Neue galenische, orale form zur verbesserung der bioverfuegbarkeit von medikamenten
EP0690710A1 (de) Verwendung von cis-9-heptadecensäure zur behandlung von psoriasis, allergien und autoimmunerkrankungen
DE60128204T2 (de) Pharmazeutische zusammensetzungen rutin und lespedeza capitata extrakt enthaltend zur behandlung von ödemen
DE3930282A1 (de) Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit
DE2654119A1 (de) Pharmazeutisches mittel mit cerebral- vasodilatatorischer wirkung und verfahren zu dessen herstellung